Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

ArriVent BioPharma (AVBP) Invested Capital (2023 - 2026)

ArriVent BioPharma has reported Invested Capital over the past 4 years, most recently at $324.0 million for Q1 2026.

  • Quarterly results put Invested Capital at $324.0 million for Q1 2026, up 59.96% from a year ago — trailing twelve months through Mar 2026 was $324.0 million (up 59.96% YoY), and the annual figure for FY2025 was $307.2 million, up 19.24%.
  • Invested Capital reached $324.0 million in Q1 2026 per AVBP's latest filing, up from $307.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $324.0 million in Q1 2026 and bottomed at -$153.2 million in Q4 2023.
  • Median Invested Capital over the past 4 years was $257.7 million (2024), compared with a mean of $156.7 million.
  • The largest annual shift saw Invested Capital soared 427.25% in 2024 before it tumbled 36.25% in 2025.
  • Over 4 years, Invested Capital stood at -$153.2 million in 2023, then skyrocketed by 268.19% to $257.7 million in 2024, then grew by 19.24% to $307.2 million in 2025, then grew by 5.45% to $324.0 million in 2026.
  • Business Quant data shows Invested Capital for AVBP at $324.0 million in Q1 2026, $307.2 million in Q4 2025, and $305.0 million in Q3 2025.